Fuxiang H1 Revenue Up 72.59%, Additive Sales Up 263%, Net Profit Turns Positive
Fuxiang Shares reported H1 2026 revenue of RMB 888 million, up 72.59% year-on-year, and net profit attributable to shareholders of RMB 177 million, swinging to a profit. Revenue from lithium battery electrolyte additives rose 263.13% to RMB 442 million. The company expanded its VC capacity to 10,000 tons per year in June 2026, having entered the sector in early 2022.
Fuxiang Shares released its semi-annual report for 2026, reporting revenue of RMB 888 million, up 72.59% year-on-year. Net profit attributable to shareholders stood at RMB 177 million, while net profit excluding non-recurring items was RMB 175 million, turning profitable. The company's three business segments developed in tandem: pharmaceutical manufacturing operated steadily, biomanufacturing microbial protein commercialization accelerated, and the lithium battery electrolyte additive business saw significant revenue growth.
In the lithium battery electrolyte additive segment, revenue for the first half of 2026 reached RMB 442 million, up 263.13% year-on-year, a 263% increase from the prior-year period. The company's VC product capacity was raised from 8,000 tons to 10,000 tons per year in June 2026, with production lines running smoothly. VC products have passed certification from South Korean customers and are being supplied to the South Korean market. The company entered this sector in January 2022, reaching 5,000 tons of capacity by end-2022 and expanding to 8,000 tons in April 2023. During the first half of 2026, the market price of VC products remained above RMB 140,000 per ton. The company plans to build a one-stop raw material supply platform to offer a richer product matrix and stable supply assurance.